Launch Milestones Sample Clauses

Launch Milestones. Subject to the terms and conditions of this Agreement, including Section 7.4, within [***] after the achievement by or on behalf of AbbVie or its Affiliates or Sublicensees of any of the following Milestone Events after the Effective Date during the Term, AbbVie shall pay to Morphic the corresponding Milestone Payment with respect to such Milestone Event on an Indication-by-Indication basis: [***] [***] [***] [***] [***] [***] Each Milestone Event in this Section 7.2.2 shall be payable once per Indication. For clarity, if a Milestone Event in this Section 7.2.2 is achieved by two (2) or more Licensed Products or Licensed Compounds for the same Indication, such Milestone Event shall only be payable once for such Indication. The maximum aggregate amount of Milestone Payments payable under this Section 7.2.2 by AbbVie with respect to Licensed Products for each Indication is [***].
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Launch Milestones. (a) Subject to the terms of Sections 6.3.4 and 6.3.5, Licensee will pay Kineta the following one-time event payments (which shall be non-creditable and non-refundable) upon the first Licensed Product achieving the following events:
Sample 1Sample 2
Launch Milestones. As to each Licensed Product, Baxalta shall pay to Precision the following non-creditable, non-refundable amounts for the first achievement of the following milestone events for such Licensed Product by Baxalta of any of its Affiliates or Sublicensees (each, a “Launch Milestone”): First Commercial Sale of the Licensed Product in [***] [***] First Commercial Sale of the Licensed Product in [***] [***] First Commercial Sale of the Licensed Product in [***] [***] First Commercial Sale of the Licensed Product in [***] [***] First Commercial Sale of the Licensed Product in [***] [***] First Commercial Sale of the Licensed Product in [***] [***] [***] Each milestone payment set forth in this Section 8.3.2 shall be payable by Baxalta upon the first achievement of the applicable Launch Milestone, and Baxalta shall provide notice to Precision of such achievement within [***] following such achievement. Following Precision’s receipt of a notice described in the immediately preceding sentence, Precision shall provide Baxalta with a corresponding invoice and Baxalta shall pay to Precision the applicable milestone payment described above within [***] after receipt of such invoice.
Sample 1Sample 2
Launch Milestones. Licensee shall notify Company immediately upon the achievement of the milestone event set forth below and shall make the corresponding nonrefundable, non-creditable payment to Company set forth below not later than thirty (30) days from receipt of the relevant invoice issued by Company following Licensee’s notice of the achievement of such milestone event: [***] € [***] [***] € [***] € [***] [***] Notwithstanding the foregoing, Licensee’s failure to notify Company in accordance with this Section 7.3 shall not relieve it of its obligation to make the payments set forth above.
Sample 1
Launch Milestones. As further partial consideration for Day One’s grant of the License to Licensee, upon the first achievement by Licensee, its Affiliate or Sublicensee of each development milestone event set forth in the table below (each a “Launch Milestone Event”), Licensee shall make the corresponding one-time, non-refundable, non-creditable payment (each a “Launch Milestone Payment”) to Day One in accordance with Section 6.7.1. 1. [*] [*]
Sample 1
Launch Milestones. Sanofi shall notify Novavax of the achievement of the launch milestone event described in Table 10.3.2 (each, a “COVID-19 Launch Milestone Event”) within [***] after the achievement thereof by Sanofi, its Affiliates, or their respective Sublicensees. Sanofi shall pay Novavax each COVID-19 launch milestone payment described in Table 10.3.2 (each, a “COVID-19 Launch Milestone Payment”) within [***] after receipt of Novavax’s corresponding invoice dated after achievement of the COVID-19 Launch Milestone Event: Table 10.3.2 COVID-19 Launch Milestones COVID-19 Launch Milestone Event COVID-19 Launch Milestone Payment First Commercial Sale in the United States of the first Licensed CIC Product Two Hundred and Twenty-Five Million Dollars ($225,000,000) The COVID-19 Launch Milestone Payment set forth in Table 10.3.2 is payable one (1)- time only, upon the First Commercial Sale of the first Licensed CIC Product in the U.S.
Sample 1
Launch Milestones. Sanofi shall notify Novavax of the achievement of each launch milestone event described in the table below (the “Adjuvant Launch Milestone Event”) within [***] after the achievement thereof. Sanofi shall pay Novavax the Adjuvant launch milestone payment described in the table below (the “Adjuvant Launch Milestone Payment”) within [***] after receipt of Novavax’s corresponding invoice dated after achievement of the Adjuvant Development Milestone Event: Table 10.4.2 Adjuvant Launch Milestones Adjuvant Launch Milestone Event Adjuvant Launch Milestone Payment First Commercial Sale in the United States of each Distinct Licensed Adjuvanted Product Fifty Million Dollars ($50,000,000) The Adjuvant Launch Milestone Payment for the Licensed Adjuvanted Product is payable upon the First Commercial Sale of each Distinct Licensed Adjuvanted Product.
Sample 1
AutoNDA by SimpleDocs
Launch Milestones. Within [**] after the first Launch by Takeda, or an Affiliate or licensee of Takeda of each Pharmaceutical Product in each of (a) Japan, (b) a Major European Country, and (c) the United States of America, Takeda shall pay to Lexicon a launch milestone payment, as set forth below: Launch Event Launch Payment ------------ -------------- First Launch in the first of either Japan, a Major European Country, or the United States of America $[**] First Launch in the second of either Japan, a Major European Country, or the United States of America $[**] First Launch in the third of either Japan, a Major European Country, or the United States of America $[**] For purposes of clarification, notwithstanding anything to the contrary, the maximum amount that Takeda will be obligated to pay to Lexicon pursuant to this Section 5.4 with respect to any single Pharmaceutical Product that is the first Pharmaceutical Product obtained from a single, particular Selected Target will be [**], and Takeda shall have no obligation to pay any amount to Lexicon under this Section 5.4 in excess of [**] with respect to the Launch of such first Pharmaceutical Product; provided, however, that in the event that one or more subsequent Pharmaceutical Products in addition to a first Pharmaceutical Product is obtained by Takeda as a consequence of use of any single, particular Selected Target, the amount to be paid by Takeda to Lexicon upon achievement of any Launch milestone event with respect to any such subsequent Pharmaceutical Product(s) under this Section 5.4 shall be equal to [**] of the amount set forth in foregoing table. The Launch milestone payment under this Section 5.4 shall be paid only once for a single Pharmaceutical Product regardless of formulations or indications. Takeda shall not be required to make the Launch milestone payment for different or additional formulations or indications for the Pharmaceutical Product. For purposes of clarification, Takeda shall have no obligation to make any Launch milestone payment under this Section 5.4 for any Ancillary Diagnostic Product.
Sample 1
Launch Milestones. Within [**] after the first Launch by Lexicon, or an Affiliate or licensee of Lexicon of each Reversion Product (other than Reversion Products licensed to Takeda pursuant to Section 4.6), in each of (a) Japan, (b) a Major European Country, and (c) the United States of America, Lexicon shall pay to Takeda launch milestone payment, as set forth below: Milestone Payment ----------------------------------------------------- Reversion Product identified by Lexicon using a High- Throughput Screening System generated by Takeda and turned over Reversion Product to Lexicon pursuant to licensed by Takeda to Sections 2.2(d) or Lexicon pursuant to Launch Event 2.3(b) and 4.5 Section 2.3(c) ------------ ----------------------- ---------------------- First Launch in the first of either Japan, a Major European Country, or the United States of America $[**] $[**] First Launch in the second of either Japan, a Major European Country, or the United States of America None $[**] First Launch in the third of either Japan, a Major European Country, or the United States of America None $[**] For purposes of clarification, notwithstanding anything to the contrary, the maximum amount that Lexicon will be obligated to pay to Takeda pursuant to this Section 5.6(b) with respect to any single Reversion Product that is the first Reversion Product obtained from a single, particular Released Target will be (i) [**] in the case of a Reversion Product identified by Lexicon using a High-Throughput Screening System generated by Takeda and turned over to Lexicon pursuant to Sections 2.2(d) or 2.3(b) and 4.5 and (ii) [**] in the case of a Reversion Product licensed by Takeda to Lexicon pursuant to Sections 2.3(c), and Lexicon shall have no obligation to pay any amount to Takeda under this Section 5.6(b) in excess of (x) [**] in the case of a Reversion Product identified by Lexicon using a High-Throughput Screening System generated by Takeda and turned over to Lexicon pursuant to Sections 2.2(d) or 2.3(b) and 4.5 and (y) [**] in the case of a Reversion Product licensed by Takeda to Lexicon pursuant to Sections 2.3(c), with respect to the Launch of such first Reversion Product; provided, however, that in the event that one or more subsequent Reversion Products in addition to a first Reversion Product is obtained by Lexicon as a consequence of use of any single, particular Released Target, the amount to be paid by Lexicon to Takeda upon achievement of any Launch milestone event with respect to any...
Sample 1

Related to Launch Milestones

  • Project/Milestones Taxpayer provides refrigerated warehousing and logistic distribution services to clients throughout the United States. In consideration for the Credit, Taxpayer agrees to invest in a new refrigeration and distribution facility in the XxXxxxxxx Park area of Sacramento, California, and hire full-time employees (collectively, the “Project”). Further, Taxpayer agrees to satisfy the milestones as described in Exhibit A (“Milestones”) and must maintain Milestones for a minimum of three (3) taxable years thereafter. In the event Taxpayer employs more than the number of full-time employees, determined on an annual full-time equivalent basis, than required in Exhibit A, for purposes of satisfying the “Minimum Annual Salary of California Full-time Employees Hired” and the “Cumulative Average Annual Salary of California Full-time Employees Hired,” Taxpayer may use the salaries of any of the full-time employees hired within the required time period. For purposes of calculating the “Minimum Annual Salary of California Full-time Employees Hired” and the “Cumulative Average Annual Salary of California Full-time Employees Hired,” the salary of any full-time employee that is not employed by Taxpayer for the entire taxable year shall be annualized. In addition, the salary of any full-time employee hired to fill a vacated position in which a full-time employee was employed during Taxpayer’s Base Year shall be disregarded.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Commercial Milestones (a) Within [*****] calendar days after the end of the first Calendar Year in which aggregate annual Net Sales for that Calendar Year for the Licensed Product in the Territory reach any threshold indicated in the Commercial Milestone Events listed below, EverInsight shall notify VistaGen of the achievement of such Commercial Milestone Event and VistaGen shall invoice EverInsight for the corresponding non-refundable, non-creditable Milestone Payment set forth below and EverInsight shall remit payment to VistaGen within [*****] Business Days after the receipt of the invoice, as described in Section 8.6 (Currency; Exchange Rate; Payments). Annual Net Sales Milestones for Licensed Product Milestone Payments (in Dollars) (each a “Commercial Milestone Event”): (1). [*****] (2). [*****] (3). [*****] (4). [*****] (5). [*****] (b) For the purposes of determining whether a Net Sales Milestone Event has been achieved, Net Sales of Licensed Product(s) in the Territory shall be aggregated. For clarity, the annual Net Sales Milestone Payments set forth in this Section 8.3 (Commercial Milestones) shall be payable only once, upon the first achievement of the applicable Commercial Milestone Event, regardless of how many times such Commercial Milestone Event is achieved. (c) If a Commercial Milestone Event in Section 8.3 (Commercial Milestones) is achieved and payment with respect to any previous Commercial Milestone Event in Section 8.3 has not been made, then such previous Commercial Milestone Event shall be deemed achieved and EverInsight shall notify VistaGen within fifteen (15) calendar days of such achievement. VistaGen shall then invoice EverInsight for such unpaid previous Commercial Milestone Event(s) and EverInsight shall pay VistaGen such unpaid previous milestone payment(s) within thirty (30) Business Days of receipt of such invoice. (d) In the event that, VistaGen believes any Commercial Milestone Event under Section 8.3(a) has occurred but EverInsight has not given VistaGen the notice of the achievement of such Commercial Milestone Event, it shall so notify EverInsight in writing and shall provide to EverInsight data, documentation or other information that supports its belief. Any dispute under this Section 8.3(d) (Commercial Milestones - subsection (d)) that relates to whether or not a Commercial Milestone Event has occurred shall be referred to the JSC to be resolved in accordance with ARTICLE 3 (Governance) and shall be subject to resolution in accordance with Section 14.10 (Dispute Resolution). The Milestone Payments made for each Commercial Milestone Event shall be non-creditable and non-refundable.

  • Sales Milestones (a) As to each Therapeutic Product, SANOFI-AVENTIS shall pay MERRIMACK up to a total of Sixty Million Dollars (US$60,000,000) upon the first achievement of the following Net Sales milestones, on a Therapeutic Product-by-Therapeutic Product basis: (i) Total Worldwide Net Sales for such Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (ii) Total Worldwide Net Sales for such Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (iii) Total Worldwide Net Sales for Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (b) Each milestone payment set forth in Section 8.4(a) shall be payable by SANOFI-AVENTIS upon the achievement of the related milestone event by SANOFI-AVENTIS and its Affiliates or sublicensees, and SANOFI-AVENTIS shall provide notice to MERRIMACK promptly upon achievement of such milestone event. SANOFI-AVENTIS shall pay MERRIMACK each such milestone payment within [**] days of such achievement of the related milestone event. (c) For purposes of clarity, more than one of the Net Sales milestones set forth above may be earned in the same four (4) consecutive calendar quarter period with respect to a Therapeutic Product. For example, if total worldwide Net Sales with respect to a given Therapeutic Product have not achieved any of the lower sales milestone thresholds set forth in clause (i) or (ii) of Section 8.3(a) above in any previous four (4) consecutive calendar quarter period, but total worldwide Net Sales with respect to such Therapeutic Product exceed $[**] in a subsequent four (4) consecutive calendar quarter period, then all three milestone payments, totaling $60 Million, payable upon achievement of the sales milestone thresholds set forth in clause (i), (ii) and (iii) of Section 8.3(a) above shall become payable to MERRIMACK hereunder.

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless it will suffer significant uncompensated economic or operational harm from the delay, (1) attainment of the same milestone has previously been delayed, or (2) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Milestone Event Milestone Payment [***] [***]

  • Targets and Milestones You may choose to develop specific additional targets and milestones which assess your performance in ITT over time – particularly if ITT trainees make up a significant proportion of your overall student body. Alternatively, you may have targets and milestones in your existing 2012-13 access agreement which you now also wish to apply to undergraduate and/or postgraduate ITT trainees. These targets may be statistical – based on how representative your entrants are and/or your retention performance – and might include annual or interim milestones to help you monitor whether you are making progress. You may wish to include criteria around the numbers of trainees in receipt of a full or partial maintenance grant, as financial data will need to be collected to determine bursary support and the data will also be accessible through the Student Loans Company for HEBSS subscribers. You may also wish to consider the TDA guidance at Annex C which gives information on specific groups that are underrepresented in the teaching profession.

  • Development Milestone Payments (i) In addition to the Closing Date Merger Consideration (less the Remaining Option Consideration and Rights Proceeds Amount, if any) and any Net TNF Sales Payments (as defined below), upon the attainment of the development ** Portions of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. milestones set forth below (each, a “Development Milestone”), Parent shall, or shall cause the Surviving Corporation to, [**] after the occurrence of each Development Milestone, deliver to the Paying Agent (for further payment to the holders of Stock Certificates and Stock Agreements outstanding immediately prior to the Effective Time), via wire transfer of immediately available funds, the respective amounts set forth below minus, in each case, the applicable Contingent Consideration Distribution Fee associated therewith and any amount designated by the Stockholders’ Representatives to be placed in the Administrative Expense Account (each, a “Development Milestone Payment” and collectively, the “Development Milestone Payments”): (A) Upon FDA approval of Reslizumab for the treatment of eosinophilic esophagitis, a cash payment of [**]; (B) Upon marketing authorization of Reslizumab for the treatment of eosinophilic esophagitis being granted by the European Commission in accordance with Regulation (EC) No. 726/2004, a cash payment of [**]; (C) If Res 5-0010 Asthma Study Completion has not occurred on or prior to the Closing Date, then upon the occurrence of the Res 5-0010 Asthma Study Completion, a cash payment of $50,000,000 (fifty million dollars) (the “Res 5-0010 Asthma Payment”); (D) Upon FDA approval of Reslizumab for any asthma indication, a cash payment of [**]; (E) Upon marketing authorization of Reslizumab for the treatment of any asthma indication being granted by the European Commission in accordance with Regulation (EC) No. 726/2004, a cash payment of [**]; and (F) Upon FDA approval of an Oral Anti-TNF Product, a cash payment of [**].

  • Project Specific Milestones In addition to the milestones stated in Section 212.5 of the Tariff, as applicable, during the term of this ISA, Interconnection Customer shall ensure that it meets each of the following development milestones: 6.1 Substantial Site work completed. On or before December 31, 2020 Interconnection Customer must demonstrate completion of at least 20% of project site construction. At this time, Interconnection Customer must submit to Interconnected Transmission Owner and Transmission Provider initial drawings, certified by a professional engineer, of the Customer Interconnection Facilities. 6.2 Delivery of major electrical equipment. On or before December 31, 2021, Interconnection Customer must demonstrate that all generating units have been delivered to Interconnection Customer’s project site.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!